Cynapsus names Dexcel execs to its board

Tweet Tomer Gold, VP of R&D, of closely-held Dexcel Pharma, and Ilan Oren, VP of business development at Dexcel, have joined the board of Cynapsus Therapeutics (TSX-V:CTH). Dexcel recently acquired 7,608,696 units of Cynapsus for $3.5-million, resulting in a 19.6% and 24% holding of Cynapsus outstanding stock on a basic and fully diluted basis, respectively. [...]

Cynapsus closes second tranche of offering

Tweet Cynapsus Therapeutics (TSX-V:CTH) has completed a second closing of its short-form prospectus offering of units for gross proceeds of $1.3-million, following the first closing of $6-million on March 1, 2013. Under the second closing, the company issued an aggregate of 2,846,000 units at a post-consolidation price of 46 cents a unit. Each unit consists [...]

Cynapsus continues prospectus offering

Tweet Cynapsus Therapeutics (TSX-V:CTH) is continuing its previously announced offering under a short-form prospectus. On March 1, the company completed a closing for gross proceeds of $6,008,000, achieving the minimum offering and resulting in the issuance of 13,061,688 units. Cynapsus said it has received a receipt for amendment no. 1 to allow for the closing [...]

Cynapsus closes $6-million offering

Tweet Cynapsus Therapeutics (TSX-V:CTH) has completed a short-form prospectus offering of units for gross proceeds of slightly more than$6-million. Concurrent with the closing of the offering, the company and holders of Series A to E debentures agreed to convert $4,031,406 in debt for common shares and warrants. In addition, the company completed a share consolidation [...]

Cynapsus files short form prospectus

Tweet Cynapsus Therapeutics (TSX-V:CTH) has received a receipt for its final short form prospectus, which was filed with the securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario, in connection with a best-efforts offering of common shares and warrants for gross proceeds of $6-million to $8-million. The prospectus will qualify the distribution [...]

Cynapsus gets Notice of Allowance for oral Parkinson’s drug patent

Tweet Cynapsus Therapeutics (TSX-V:CTH) has received a notice of allowance from the U.S. Patent and Trademark Office for the patent application covering critical claims directed to thin film compositions containing apomorphine formulated for sublingual administration. The allowed application will be the first to emerge as a U.S. patent from the company’s patent application filings directed [...]

Cynapsus files short-form prospectus

Tweet ynapsus Therapeutics (TSX-V:CTH) has filed a preliminary short-form prospectus with the securities regulatory authorities in British Columbia, Alberta and Ontario in connection with a best-effort offering of common shares and warrants of Cynapsus for gross proceeds of $6-million to $8-million. Final pricing and determination of the number of common shares and warrants to be [...]

Cynapsus drug one of top ten neurology projects

Tweet Cynapsus Therapeutics’ (TSX-V:CTH) APL-130277 for Parkinson’s disease was recognized as one of the Top Ten Neurology Projects to Watch in 2012 by a joint selection committee, including Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain and editor of the highly respected biotechnology publication NeuroPerspective, as well as with Elsevier [...]

Cynapsus closes private placement

Tweet Cynapsus Therapeutics (TSX-V:CTH) has closed a brokered private placement of 3.4 million units at a price of 5 cents a unit to raise gross proceeds of $170,000 for working capital purposes. Each Unit consists of one common share and one warrant, with each warrant entitling the holder to acquire an additional common share at [...]

Cynapsus to raise $7-million in unit offering

Tweet Cynapsus Therapeutics (TSX-V:CTH) has signed a term sheet with a health care/life sciences-focused institutional investment group to be the lead investor in a short-form prospectus offering of $7-million of units, comprising common shares and warrants. Moody Capital Solutions will act as the lead placement agent. “We are delighted to have a quality lead investor [...]

Next Page »